Navigation Links
Two Studies Test Impact of Drugs to Slow Progression of Type 1 Diabetes
Date:6/27/2011

ROCKVILLE, Md., June 27, 2011 /PRNewswire-USNewswire/ -- Results of two studies testing drugs to slow or stop the immune system's attack on insulin-producing cells in people newly diagnosed with type 1 diabetes will be presented at the American Diabetes Association's (ADA) 71st Scientific Sessions in San Diego and simultaneously published online in the Lancet. The studies were conducted by the National Institutes of Health's international network of researchers, Type 1 Diabetes TrialNet Study Group, led by the National Institute of Diabetes and Digestive and Kidney Diseases.

Both TrialNet studies aimed to preserve secretion of insulin, the hormone that controls blood glucose levels; one with the drug abatacept, and the other with a vaccine called glutamic acid decarboxylase (GAD).  When type 1 diabetes is diagnosed, most patients retain a limited ability to make insulin, which is generally lost rapidly over the following one to two years. All study participants received intensive management of their diabetes during the trial, with a goal of keeping HbA1c levels within current ADA recommendations.

In the first study, abatacept (Orencia), an immune system modulator currently used to treat several inflammatory diseases, was evaluated in 112 people, ages 6 to 36, with newly diagnosed  type 1 diabetes. Participants were randomized to receive injections of either abatacept or placebo over two years. The group treated with abatacept had a 9.6 month delay in the progression of loss of insulin production.  After two years, a marker for the production of insulin was 59 percent higher in the participants treated with abatacept compared to the placebo group. Long-term retention of the ability to make even small amounts of insulin is associated with better glucose control and improved outcomes in diabetes.  

In the second study, GAD-alum, an antigen based therapy aiming to suppress the immune response, was tested in 14
'/>"/>

SOURCE TrialNet
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Studies Show Effect of BYDUREON™ on A1C and Weight for Up to Three Years
2. Pearl Therapeutics Advances Its Long-Acting Bronchodilator Combination Product Candidate into Four Additional Phase 2 Studies
3. Best of ASCO Features Two Studies Led by US Oncology Research Affiliated Physicians
4. Data from Clinical Studies of bioTheranostics CancerTYPE ID® and Breast Cancer Index(SM) Molecular Diagnostic Tests Presented at ASCO 2011 Annual Meeting
5. Pharmacyclics Reports Recent Developments From Clinical Studies of its Btk Inhibitor PCI-32765
6. Genomic Health Presents Ten New Studies in Breast, Colon and Prostate Cancers at the American Society of Clinical Oncology (ASCO) Annual Meeting
7. Additional Data From Multiple Phase 1 and 2 Studies of S*BIOs Novel JAK2 Inhibitor SB1518 Demonstrate Safety and Efficacy for Treatment of Symptomatic Myelofibrosis (MF)
8. Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis
9. Genomic Health Announces Ten Studies Covering Breast, Colon and Prostate Cancers Accepted for Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting
10. Lilly Oncology to Unveil Data From More Than 30 Studies at ASCO
11. New Studies Support CardioFocus HeartLight™ Endoscopic Ablation Systems Notable Treatment Results for Paroxysmal Atrial Fibrillation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... Ariz. , Dec. 17, 2014  Beamz ... state-of-the-art interactive music products, today announced that it ... a leading manufacturer and supplier of innovative prosthetic, ... As part of the agreement, RSL Steeper ... bundled solution specifically configured for use within UK ...
(Date:12/17/2014)... -- IGI Laboratories, Inc. (NYSE MKT: IG; "IGI" or the ... $125 million aggregate principal amount of 3.75% Convertible Senior ... and sold only to qualified institutional buyers pursuant to ... amended (the "Securities Act"). The Notes bear ... payable semiannually in arrears on June 15 and December ...
(Date:12/17/2014)... HOUSTON , Dec. 17, 2014 ... Autism Approved ( http://bit.ly/1382OkS ) program seal ... autism community. The program highlights medical practices, materials ... considered "autism-community friendly." Children affected by ... that can be exacerbated by ingredients found in ...
Breaking Medicine Technology:Beamz Interactive, Inc. Signs UK Distribution Agreement with RSL Steeper Limited 2Beamz Interactive, Inc. Signs UK Distribution Agreement with RSL Steeper Limited 3IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 2IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 3IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 4Parents Of Children With Autism Spectrum Disorder Have New Options When Administering Medications 2Parents Of Children With Autism Spectrum Disorder Have New Options When Administering Medications 3
... 2011 ORTHOCON, Inc., a developer of implantable products designed ... bone, today announced the U.S. launch of its first commercial ... The HEMA SORB Absorbable Bone Hemostat Matrix ... putty that is designed to rapidly stop bleeding when applied ...
... Reportlinker.com announces that a new market ... Drug Device Combination Market ... the New Business Model for Growth and ... Drug Device Combination Market to ...
Cached Medicine Technology:ORTHOCON® Announces U.S. Market Launch of HEMASORB® 2Reportlinker Adds Drug Device Combination Market to 2016 - Technological Convergence to be the New Business Model for Growth and Profitability 2Reportlinker Adds Drug Device Combination Market to 2016 - Technological Convergence to be the New Business Model for Growth and Profitability 3
(Date:12/19/2014)... This is a professional and in-depth ... industry with a focus on the Chinese market. The ... the Gliquidone manufacturers and is a valuable source of ... the industry. , Firstly, the report provides a basic ... manufacturing technology. Then, the report explores the international and ...
(Date:12/19/2014)... new study suggests a possible link between certain menopause ... sweats -- and higher rates of hip fractures and ... affecting about 60 percent of women. The hormonal changes ... then face a higher risk of weakened bones and ... or severe menopausal symptoms are more likely to have ...
(Date:12/19/2014)... -- Traveling through the same U.S. airport gate, one ... within a four-hour time span, illustrating just how easily ... "The exposures in this report were not prolonged and ... highlighting the fact that measles is highly contagious," wrote ... specialist at the U.S. Centers for Disease Control and ...
(Date:12/17/2014)... 17, 2014 Dr. Myo Nwe is the ... Diet of the Future” and co-founder of the Ace Medical ... Dr. Nwe takes a broad look at the industry of ... under scientific scrutiny. On film and in television shows, however, ... toward the social aspects and played for basic laughs, which ...
(Date:12/17/2014)... CA (PRWEB) December 17, 2014 A group ... Center for Longevity, today, in reaction to a recent statement ... science of brain training and derogated the efficacy of all ... they agreed with the parts of the center’s statement critical ... believed the center had also overstated its case, in a ...
Breaking Medicine News(10 mins):Health News:Gliquidone Industry Global and China Analysis for 2019, Now Available at ReportsnReports.com 2Health News:Gliquidone Industry Global and China Analysis for 2019, Now Available at ReportsnReports.com 3Health News:Gliquidone Industry Global and China Analysis for 2019, Now Available at ReportsnReports.com 4Health News:Gliquidone Industry Global and China Analysis for 2019, Now Available at ReportsnReports.com 5Health News:Gliquidone Industry Global and China Analysis for 2019, Now Available at ReportsnReports.com 6Health News:Severe Hot Flashes During Menopause May Raise Hip Fracture Risk Later: Study 2Health News:Arriving Now at Gate 42: Measles 2Health News:Arriving Now at Gate 42: Measles 3Health News:Obesity Should Not Be a Hollywood Punchline, Weight Loss Doc Says 2Health News:Scientists to Stanford: Research Shows Brain Exercises Can Work 2Health News:Scientists to Stanford: Research Shows Brain Exercises Can Work 3Health News:Scientists to Stanford: Research Shows Brain Exercises Can Work 4
... investigates the challenges that pen and paper workarounds ... of electronic health records. Understanding these challenges may ... health IT. Focusing on referrals by primary ... specialists back to the referring physician, "Paper Persistence, ...
... The American Society of Clinical Oncology (ASCO) Annual Meeting, ... for treating recurrent gliobastoma (GBM) has a favorable safety ... more than the current median survival rate. Patients ... Center, University of California, San Francisco and Columbia University, ...
... the most vulnerable group are the elderly. Writing in ... in New Zealand suggest that emergency response plans must ... regards to the personal and social resources they have ... University in Palmerston North, point out that elderly citizens ...
... the arteries is one of the leading causes of death. ... growth of fibrous plaques, which leads to narrowing or occlusion ... The persistence of the inflammatory reaction is due to a ... So-called dendritic cells are known to play a central role ...
... quality care for young people do not always provide the ... found. As our population ages and requires more healthcare, ... for the over 65s and implement programs to meet their ... director at St. Michael,s Hospital. The study, published in ...
... HealthDay Reporter , THURSDAY, June 2 (HealthDay News) -- The ... bacteria in Europe should serve as a red flag ... mutating and changing. They,re not necessarily becoming more severe, but ... attending physician in infectious diseases at North Shore University Hospital ...
Cached Medicine News:Health News:Paper and computer workarounds challenge but may improve health IT 2Health News:Paper and computer workarounds challenge but may improve health IT 3Health News:Study finds vaccine extends recurrent GBM survival rates by 2 to 3 times 2Health News:Study finds vaccine extends recurrent GBM survival rates by 2 to 3 times 3Health News:Study finds vaccine extends recurrent GBM survival rates by 2 to 3 times 4Health News:Study finds vaccine extends recurrent GBM survival rates by 2 to 3 times 5Health News:Study finds vaccine extends recurrent GBM survival rates by 2 to 3 times 6Health News:Study finds vaccine extends recurrent GBM survival rates by 2 to 3 times 7Health News:Study finds vaccine extends recurrent GBM survival rates by 2 to 3 times 8Health News:Study finds vaccine extends recurrent GBM survival rates by 2 to 3 times 9Health News:Study finds vaccine extends recurrent GBM survival rates by 2 to 3 times 10Health News:Study finds vaccine extends recurrent GBM survival rates by 2 to 3 times 11Health News:Study finds vaccine extends recurrent GBM survival rates by 2 to 3 times 12Health News:Helping the aged during natural disasters 2Health News:Fast track to vascular disease 2Health News:Fast track to vascular disease 3Health News:Not all hospitals treat elderly the same 2Health News:Deadly E. Coli Strain in Europe Should Serve as Warning, Experts Say 2Health News:Deadly E. Coli Strain in Europe Should Serve as Warning, Experts Say 3
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Deflected large type, opening width 7.0 mm and length 5 mm....
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Deflected large type, opening width 8.0 mm and length 5 mm....
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Deflected large type, opening width 10.0 mm and length 10 mm....
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Deflected large type, opening width 8.0 mm and length 5 mm....
Medicine Products: